Caribou Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $1.50M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $2.40M | $-0.26 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | $3.90M | $-0.28 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $2.20M | $-0.30 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $2.70M | $-0.58 | $-0.35 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $2.40M | $-0.43 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | After market close | $2.10M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $2.00M | $-0.38 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | After market close | – | – | – |
Press releases
Announcements Caribou Biosciences filed with the SEC
Caribou Biosciences to Evaluate Strategic Alternatives
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CB-010 ANTLER Phase 1 trial update and KOL discussion Transformative genome-edited therapies for patients June 2, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Expands Clinical Development of CB- 010 with FDA Clearance of IND in Lupus April 4, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Third Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ANTLER Phase 1 trial results summary Transformative genome-edited therapies for patients July 13, 2023
Other events · EX-99.1 to Form 8-K/A
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CB-010 clinical program update Transformative genome-edited therapies for patients July 13, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ANTLER Phase 1 trial results summary Transformative genome-edited therapies for patients July 13, 2023
Other events · EX-99.1 to Form 8-K
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K